865864-31-9

Basic information

• Product Name: 4-(benzyl(methyl)amino)butan-2-ol
• Synonyms: 4-(benzyl(methyl)amino)butan-2-ol
• CAS NO: 865864-31-9
• Molecular Weight: 193.289
• Mol File: 865864-31-9.mol

Chemical Properties

• CAS DataBase Reference: 4-(benzyl(methyl)amino)butan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyl(methyl)amino)butan-2-ol(865864-31-9)
• EPA Substance Registry System: 4-(benzyl(methyl)amino)butan-2-ol(865864-31-9)

Safety Data

• Hazardous Substances Data: 865864-31-9(Hazardous Substances Data)

Upstream product

• 16635-00-0 1-(N-benzyl-N-methyl)-amino-butan-3-one 
• 103-67-3 benzyl-methyl-amine 
• 59744-08-0 toluene-4-sulfonic acid 3-hydroxybutyl ester 

Relevant articles and documents

Aliphatic Amino Azides as Key Building Blocks for Efficient Polyamine Syntheses

New routes to open-chain polyamines have been developed using aliphatic amino azides as common precursors for the construction of the carbon-nitrogen framework.These α,ω-diaminoalkane synthetic equivalents were combined with (ω-halogenalkyl)dichloroboranes to extend the polyamine chain from the azido moiety.An extension from the free amino group can also be achieved via a Michael type addition with acrylonitrile or a reductive amination with a γ-azido ketone.Further transformations led to a large variety of regioselectively C- or (and) N-substituted polyamines.

Synthesis route of 4-alkyl secondary amino-2-butanol compound

According to the invention, 4-hydroxy- 2-butanone is used as an initial raw material, the 4-alkyl secondary amino -2-butanol compound is prepared through sulfonyl chloride reagent substitution reaction, reduction reaction and organic amine ammonolysis reaction, and the novel synthetic route solves the problems of many byproducts, low yield, expensive raw materials, toxicity, harmlessness and the like in the prior art. Compared with the prior art, the method is low in raw material cost, stable and mild in reaction, few in reaction byproducts, high in yield, environmentally friendly and suitablefor synthesis of a series of organic matters. Meanwhile, an amplification test is passed through the technology disclosed by the invention, and a good application prospect is achieved.

CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

PHARMACEUTICAL COMPOUNDS

The present invention relates to inhibitors of serotonin and/or norepinephrine reuptake and specifically provides compounds of formula (I): wherein A is selected from -O- and -S-; X is selected from C1-C8 alkyl, C2-C8 alkenyl, and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from phenyl, pyrrolidinyl, piperidinyl, morpholinyl, halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from (a), (b), (c), (d), (e), (f) where R3, R4and R5 are independently selected from hydrogen, halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R6 and R7 are independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R8 is selected from chloro, bromo, iodo, C1-C4alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R1 and R2 are each independently hydrogen or C1-C4 alkyl; or pharmaceutically acceptable salts thereof; or compositions thereof and methods of using the same.

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.